報價延遲最少15分鐘:2026/04/16 13:18 EDT
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
1.14 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-0.25/-0.68
|
|
企業價值
64.51M
|
| 資產負債 |
|
每股賬面淨值
0.24
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
42.00K
|
|
每股收益
0.00
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比較之報價最少15分鐘延遲 (夜盤時段除外)
|
業務概覽
|
|||
| Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to perform. Its product candidates are: EB613, which is being developed as an oral, osteoanabolic (bone-building) tablet treatment for osteoporosis; EB612, being developed as an oral PTH(1-34) tablet peptide replacement therapy for patients with hypoparathyroidism; EB618, an Oral GLP-1 being developed to tackle obesity; and Oral GLP-2, a peptide tablet alternative for patients suffering from short bowel syndrome. The company operates in Israel. |
